Oxford vaccines spinout Vaccitech raises $168M, laying groundwork for an IPO

The Series B round of funding for University of Oxford spinout Vaccitech includes the type of financial backers that could support an IPO. While Vaccitech might be best known for its association with AstraZeneca's Covid-19 vaccine, the startup also has programs for other infectious diseases and cancer.